Drug DevelopmentScynexis has full rights to the next-generation antifungal SCY-247, which is in Phase 1 development.
Financial StabilityScynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.
Partnerships And CollaborationsThe company received a $10M milestone payment from GSK following the submission of clinical study reports for the FURI, CARES, and NATURE studies.